Novogen Appoints Three New Directors SYDNEY, AUSTRALIA--(Marketwire - September 20, 2010) -  Pharmaceutical development company, Novogen Limited (ASX: NRT) (NASDAQ: NVGN) has appointed three new Directors. Of the three...

Marshall Edwards Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...

Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - September 29, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL), a pharmaceutical company specializing in clinical development of oncology drugs, today...